Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Computed Tomography | Review

Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma

Authors: Danni Li, Xuran Li, Jun Zhao, Fei Tan

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are often aggressive, making advanced disease very difficult to treat using contemporary modalities, such as surgery, radiation therapy, and chemotherapy. However, targeted therapy, e.g., cetuximab, an epidermal growth factor receptor inhibitor, has demonstrated survival benefit in HNSCC patients with locoregional failure or distant metastasis. Molecular imaging aims at various biomarkers used in targeted therapy, and nuclear medicine-based molecular imaging is a real-time and non-invasive modality with the potential to identify tumor in an earlier and more treatable stage, before anatomic-based imaging reveals diseases. The objective of this comprehensive review is to summarize recent advances in nuclear medicine-based molecular imaging for HNSCC focusing on several commonly radiolabeled biomarkers. The preclinical and clinical applications of these candidate imaging strategies are divided into three categories: those targeting tumor cells, tumor microenvironment, and tumor angiogenesis. This review endeavors to expand the knowledge of molecular biology of HNSCC and help realizing diagnostic potential of molecular imaging in clinical nuclear medicine.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef
2.
Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 2011;17:4425–38.PubMedPubMedCentralCrossRef
3.
4.
Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 2019;20:1295–305.PubMedCrossRef
5.
Leblanc O, Vacher S, Lecerf C, Jeannot E, Klijanienko J, Berger F, et al. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. Cancer Biol Med. 2020;17:208–17.PubMedPubMedCentralCrossRef
6.
7.
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008;112:2635–45.PubMedCrossRef
8.
Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–7.PubMedCrossRef
9.
Ehlerding EB, England CG, McNeel DG, Cai W. Molecular imaging of immunotherapy targets in cancer. J Nucl Med Offl Publ Soc Nucl Med. 2016;57:1487–92.
10.
11.
Castaldi P, Leccisotti L, Bussu F, Miccichè F, Rufini V. Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital. 2013;33:1–8.PubMedPubMedCentral
12.
Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666–72.PubMedCrossRef
13.
Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885–92.PubMed
14.
Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–32.PubMedCrossRef
15.
16.
Hoeben BAW, Molkenboer-Kuenen JDM, Oyen WJG, Peeters WJM, Kaanders JHAM, Bussink J, et al. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer. 2011;129:870–8.PubMedCrossRef
17.
van Dijk LK, Hoeben BAW, Stegeman H, Kaanders JHAM, Franssen GM, Boerman OC, et al. 111In-cetuximab-F(ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108:484–8.CrossRef
18.
van Dijk LK, Boerman OC, Franssen GM, Lok J, Kaanders JHAM, Bussink J. Early response monitoring with 18F-FDG PET and cetuximab-F(ab’)2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. J Nucl Med Offl Publ Soc Nucl Med. 2014;55:1665–70.
19.
van Dijk LK, Hoeben BAW, Kaanders JHAM, Franssen GM, Boerman OC, Bussink J. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab’)2. J Nucl Med Offl Publ Soc Nucl Med. 2013;54:2118–24.
20.
van Dijk LK, Yim C-B, Franssen GM, Kaanders JHAM, Rajander J, Solin O, et al. PET of EGFR with (64) Cu-cetuximab-F(ab’)2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media Mol Imaging. 2016;11:65–70.PubMedCrossRef
21.
van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, et al. PET imaging of zirconium-89 labelled cetuximab: a phase I trial in patients with head and neck and lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;122:267–73.CrossRef
22.
Even AJG, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJL, Heukelom J, Tesselaar MET, et al. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget. 2017;8:3870–80.PubMedCrossRef
23.
Benedetto R, Massicano AVF, Crenshaw BK, Oliveira R, Reis RM, Araújo EB, et al. 89Zr-DFO-cetuximab as a molecular imaging agent to identify cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biother Radiopharm. 2019;34:288–96.PubMedPubMedCentralCrossRef
24.
Li W, Niu G, Lang L, Guo N, Ma Y, Kiesewetter DO, et al. PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging. 2012;39:300–8.PubMedCrossRef
25.
Burley TA, Da Pieve C, Martins CD, Ciobota DM, Allott L, Oyen WJG, et al. Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models. J Nucl Med Offl Publ Soc Nucl Med. 2019;60:353–61.
26.
Niu G, Li Z, Xie J, Le Q-T, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med Offl Publ Soc Nucl Med. 2009;50:1116–23.
27.
Song IH, Noh Y, Kwon J, Jung JH, Lee BC, Kim KI, et al. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model. Oncotarget. 2017;8:92090–105.PubMedPubMedCentralCrossRef
28.
Ku A, Kondo M, Cai Z, Meens J, Li MR, Ailles L, et al. Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab’)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab’)2 - implications for a PET theranostic strategy. EJNMMI Radiopharm Chem. 2021;6:25.PubMedPubMedCentralCrossRef
29.
Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell. 2018;33:1061-77.e6.PubMedPubMedCentralCrossRef
30.
Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer (Oxford, England: 1990). 2010;46:1271–7.CrossRef
31.
Spiegelberg D, Nilvebrant J. CD44v6-targeted imaging of head and neck squamous cell carcinoma: antibody-based approaches. Contrast Media Mol Imaging. 2017;2017:2709547.PubMedPubMedCentralCrossRef
32.
Börjesson PKE, Jauw YWS, Boellaard R, de Bree R, Comans EFI, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res Offl J Am Assoc Cancer Res. 2006;12:2133–40.CrossRef
33.
Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med Offl Publ Soc Nucl Med. 2000;41:1999–2010.
34.
Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer. 2002;99:396–402.PubMedCrossRef
35.
Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res Offl J Am Assoc Cancer Res. 2000;6:3046–55.
36.
Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2003;52:576–82.PubMedCrossRef
37.
Odenthal J, Rijpkema M, Bos D, Wagena E, Croes H, Grenman R, et al. Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma. Sci Rep. 2018;8:10467.PubMedPubMedCentralCrossRef
38.
39.
Haylock A-K, Spiegelberg D, Nilvebrant J, Sandström K, Nestor M. In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study. EJNMMI Res. 2014;4:11.PubMedPubMedCentralCrossRef
40.
Haylock A-K, Spiegelberg D, Mortensen AC, Selvaraju RK, Nilvebrant J, Eriksson O, et al. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. Int J Oncol. 2016;48:461–70.PubMedCrossRef
41.
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–52.PubMedCrossRef
42.
Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, et al. Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy. Front Endocrinol. 2021;12:679000.CrossRef
43.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.PubMedCrossRef
44.
Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, et al. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics. 2018;8:6088–100.PubMedPubMedCentralCrossRef
45.
Stafford ND, Condon LT, Rogers MJC, MacDonald AW, Atkin SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci. 2003;28:314–9.PubMedCrossRef
46.
Loh KS, Waser B, Tan LKS, Ruan RS, Stauffer E, Reubi JC. Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch. 2002;441:444–8.PubMedCrossRef
47.
Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, et al. Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol. 2012;126:1261–70.PubMedCrossRef
48.
Bennink RJ, van der Meulen FW, Freling NJ, Booij J. Somatostatin receptor scintigraphy in nasopharyngeal carcinoma. Clin Nucl Med. 2008;33:558–61.PubMedCrossRef
49.
Doan JT, Arnold CD. An unusual case of positive somatostatin receptor scintigraphy in squamous cell carcinoma of head and neck. Clin Nucl Med. 2011;36:380–1.PubMedCrossRef
50.
Viswanathan K, Sadow PM. Somatostatin receptor 2 is highly sensitive and specific for Epstein-Barr virus-associated nasopharyngeal carcinoma. Hum Pathol. 2021;117:88–100.PubMedCrossRef
51.
Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber L-M, et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021;12:117.PubMedPubMedCentralCrossRef
52.
Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J, et al. Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;49(4):1360–73.PubMedCrossRef
53.
Unterrainer M, Maihoefer C, Cyran CC, Bartenstein P, Niyazi M, Albert NL. 68Ga-DOTATATE PET/CT Reveals epstein-barr virus-associated nasopharyngeal carcinoma in a case of suspected sphenoid wing meningioma. Clin Nucl Med. 2018;43:287–8.PubMedCrossRef
54.
Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1365–72.PubMedCrossRef
55.
Schartinger VH, Dudás J, Url C, Reinold S, Virgolini IJ, Kroiss A, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2015;42:20–4.PubMedCrossRef
56.
Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.PubMedCrossRef
57.
Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.PubMedCrossRef
58.
Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, et al. Correlation between (68)Ga-DOTA-NOC PET/CT and (18)F-FDG PET/CT in EBV-positive undifferentiated nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2015;42:1162–3.PubMedCrossRef
59.
Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, et al. 68Ga-DOTA-peptide: a novel molecular biomarker for nasopharyngeal carcinoma: 68Ga-DOTA-peptide in NPC. Head Neck. 2016;38:E76–80.PubMedCrossRef
60.
Zhu W, Zhang J, Singh A, Kulkarni HR, Baum RP. Metastatic nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor radionuclide therapy. Clin Nucl Med. 2019;44:989–90.PubMedCrossRef
61.
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.PubMedCrossRef
62.
63.
Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-ad V, Pribitkin E, et al. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 2014;41:217–34.PubMedCrossRef
64.
Kim J, Bae J-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147.PubMedPubMedCentral
65.
Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019;18:63.PubMedPubMedCentralCrossRef
66.
67.
Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:84.PubMedPubMedCentralCrossRef
68.
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63.PubMedCrossRef
69.
Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11:3203–11.PubMedPubMedCentralCrossRef
70.
Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem. 2014;57:3053–74.PubMedCrossRef
71.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med Offl Publ Soc Nucl Med. 2019;60:801–5.
72.
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med Offl Publ Soc Nucl Med. 2018;59:1415–22.
73.
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.PubMedPubMedCentralCrossRef
74.
Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hartmann E, et al. Improved cancer detection in Waldeyer’s tonsillar ring by 68Ga-FAPI PET/CT imaging. Eur J Nucl Med Mol Imaging. 2021;48:1178–87.PubMedCrossRef
75.
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915–31.PubMedCrossRef
76.
Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73–86.PubMedCrossRef
77.
Gu B, Xu X, Zhang J, Ou X, Xia Z, Guan Q, et al. The added value of 68Ga-FAPI-04 PET/CT in patients with head and neck cancer of unknown primary with 18 F-FDG negative findings. J Nucl Med. 2022;63:875–81.PubMedCrossRef
78.
Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47:2836–45.PubMedPubMedCentralCrossRef
79.
Zhao L, Pang Y, Zheng H, Han C, Gu J, Sun L, et al. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3606–17.PubMedCrossRef
80.
Linz C, Brands RC, Kertels O, Dierks A, Brumberg J, Gerhard-Hartmann E, et al. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity—initial experience and comparison to [18F]FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging. 2021;48:3951–60.PubMedPubMedCentralCrossRef
81.
82.
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32.PubMedCrossRef
83.
Qin C, Liu F, Huang J, Ruan W, Liu Q, Gai Y, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48:3228–37.PubMedCrossRef
84.
Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:6–13.PubMedCrossRef
85.
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.PubMedPubMedCentralCrossRef
86.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;393:156–67.CrossRef
87.
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.PubMedCrossRef
88.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord J-P, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC. JAMA Oncol. 2019;5:195–203.PubMedCrossRef
89.
Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.PubMedPubMedCentralCrossRef
90.
Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, et al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016;8:583–600.PubMedCrossRef
91.
van der Veen EL, Bensch F, Glaudemans AWJM, Lub-de Hooge MN, de Vries EGE. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treat Rev. 2018;70:232–44.PubMedCrossRef
92.
England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, et al. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:110–20.PubMedCrossRef
93.
Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P, et al. Immuno-PET imaging of 89Zr labeled anti-PD-L1 domain antibody. Mol Pharm. 2018;15:1674–81.PubMedCrossRef
94.
Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112:E6506–14.PubMedPubMedCentralCrossRef
95.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.PubMedCrossRef
96.
Li D, Li X, Yang J, Shi Z, Zhang L, Li R, et al. Nivolumab-DTPA-based PD-1 imaging reveals structural and pathological changes in colorectal carcinoma. Front Bioeng Biotechnol. 2022;10: 839756.PubMedPubMedCentralCrossRef
97.
Li D, Wang C, Zhang D, Peng Y, Ren S, Li X, et al. Preliminary application of 125I–nivolumab to detect PD-1 expression in colon cancer via SPECT. J Radioanal Nucl Chem. 2018;318:1237–42.CrossRef
98.
99.
Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017;6: e1356153.PubMedPubMedCentralCrossRef
100.
Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-Cell infiltration. Clin Cancer Res. 2018;24:5368–80.PubMedPubMedCentralCrossRef
101.
Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology. 2017;6: e1329071.PubMedPubMedCentralCrossRef
102.
103.
Debordeaux F, Chansel-Debordeaux L, Pinaquy J-B, Fernandez P, Schulz J. What about αvβ3 integrins in molecular imaging in oncology? Nucl Med Biol. 2018;62–63:31–46.PubMedCrossRef
104.
Fabricius E-M, Wildner G-P, Kruse-Boitschenko U, Hoffmeister B, Goodman SL, Raguse J-D. Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med. 2011;2:9–19.PubMedCrossRef
105.
Ahmedah HT, Patterson LH, Shnyder SD, Sheldrake HM. RGD-binding integrins in head and neck cancers. Cancers (Basel). 2017;9:56.PubMedCentralCrossRef
106.
Nieberler M, Reuning U, Reichart F, Notni J, Wester H-J, Schwaiger M, et al. Exploring the role of RGD-recognizing integrins in cancer. Cancers. 2017;9:116.PubMedCentralCrossRef
107.
Beer AJ, Grosu A-L, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res Offl J Am Assoc Cancer Res. 2007;13:6610–6.CrossRef
108.
Lobeek D, Rijpkema M, Terry SYA, Molkenboer-Kuenen JDM, Joosten L, van Genugten EAJ, et al. Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:2647–55.PubMedPubMedCentralCrossRef
109.
Durante S, Dunet V, Gorostidi F, Mitsakis P, Schaefer N, Delage J, et al. Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study. EJNMMI Res. 2020;10:47.PubMedPubMedCentralCrossRef
110.
Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022;20:49.PubMedPubMedCentralCrossRef
111.
Terry SYA, Abiraj K, Lok J, Gerrits D, Franssen GM, Oyen WJG, et al. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts? J Nucl Med Offl Publ Soc Nucl Med. 2014;55:1849–55.
112.
Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, et al. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? J Nucl Med Offl Publ Soc Nucl Med. 2014;55:1878–84.
113.
Chen S-H, Wang H-M, Lin C-Y, Chang JT-C, Hsieh C-H, Liao C-T, et al. RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study. Eur J Nucl Med Mol Imaging. 2016;43:1621–9.PubMedCrossRef
114.
Roesch S, Lindner T, Sauter M, Loktev A, Flechsig P, Müller M, et al. Comparison of the RGD motif-containing αvβ6 integrin-binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC. J Nucl Med Offl Publ Soc Nucl Med. 2018;59:1679–85.
115.
Quigley NG, Steiger K, Hoberück S, Czech N, Zierke MA, Kossatz S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2021.
116.
117.
Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.PubMedCrossRef
118.
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate-specific membrane antigen is produced in tumor- associated neovasculature. Clin Cancer Res. 1999;5(10):2674–81.PubMed
119.
Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012;25:1079–85.PubMedCrossRef
120.
Pandit-Taskar N, O’Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, et al. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015;5:28.PubMedPubMedCentralCrossRef
121.
Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2017;42:e218–20.PubMedCrossRef
122.
Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med. 2017;58:1938–42.PubMedCrossRef
Metadata
Title
Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma
Authors
Danni Li
Xuran Li
Jun Zhao
Fei Tan
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03559-5

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Radiated glioblastoma cell-derived exosomal circ_0012381 induce M2 polarization of microglia to promote the growth of glioblastoma by CCL2/CCR2 axis

Research

Effects of high-intensity interval training on improving arterial stiffness in Chinese female university students with normal weight obese: a pilot randomized controlled trial

Research

Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients

Research

The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics

Research

Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis

Research

 Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits